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AbsTrACT
background Chitayat-hall syndrome, initially described 
in 1990, is a rare condition characterised by distal 
arthrogryposis, intellectual disability, dysmorphic features 
and hypopituitarism, in particular growth hormone 
deficiency. the genetic aetiology has not been identified.
Methods and results We identified three unrelated 
families with a total of six affected patients with the 
clinical manifestations of Chitayat-hall syndrome. 
through whole exome or whole genome sequencing, 
pathogenic variants in the MAGEL2 gene were identified 
in all affected patients. All disease-causing sequence 
variants detected are predicted to result in a truncated 
protein, including one complex variant that comprised a 
deletion and inversion.
Conclusions Chitayat-hall syndrome is caused by 
pathogenic variants in MAGEL2 and shares a common 
aetiology with the recently described Schaaf-Yang 
syndrome. the phenotype of MAGEL2-related disorders 
is expanded to include growth hormone deficiency as an 
important and treatable complication.
InTroduCTIon
In 1990 Chitayat et al1 reported siblings with 
distal arthrogryposis, hypopituitarism, intellec-
tual disability and dysmorphisms. This condition 
is known as Chitayat-Hall syndrome or distal 
arthrogryposis with hypopituitarism including 
growth hormone (GH) deficiency, mental retar-
dation and facial anomalies (OMIM #208080). 
A similar phenotype has been described in other 
patients, including one case with consanguineous 
parents. Autosomal recessive inheritance has been 
suggested based on the history of consanguinity and 
sibling recurrence.1–3 Here we report six patients 
with Chitayat-Hall syndrome from four fami-
lies, including updated information on the female 
proband originally reported by Chitayat et al.1 All 
patients were found to have truncating sequence 
variants in the MAGEL2 gene, including the first 
reported disease-causing complex rearrangement 
involving MAGEL2. Patients with truncating 
variants in MAGEL2 have been described to 
have Schaaf-Yang syndrome (SHFYNG; OMIM 
#615547), a variable phenotype characterised 
by intellectual disability, early feeding difficulties 
followed by excessive weight gain in some patients, 
hypotonia, and contractures ranging in severity 
from distal arthrogryposis to severe arthrogryp-
osis multiplex congenita.4–6 We demonstrate that 
Chitayat-Hall syndrome has the same aetiology as 
SHFYNG, and that GH deficiency is an important 
feature of this condition.
ClInICAl rePorTs
The cohort was recruited from centres across 
Canada. All patients initially received a clin-
ical diagnosis of Chitayat-Hall syndrome from a 
medical geneticist, with the exception of patient 
4-I, who did not have a clinical diagnosis but was 
noted to have similar features. Clinical features 
are summarised in table 1. Pedigrees are shown in 
figure 1 and patient photographs in figure 2. Full 
phenotype reports are found in the online supple-
mentary clinical information. Here we provide 
detailed information regarding GH deficiency in 
this cohort. Consent to publish clinical information 
was obtained from all families.
Patient 1-I presented with poor growth velocity. 
She was treated with somatotropin until age 17. 
Her final height is on the 10th percentile. In addi-
tion to GH deficiency, she has central hypothy-
roidism and is treated with levothyroxine.1 She has 
not been formally investigated for hypogonadism, 
but has amenorrhoea.
At 4 months of age patient 2-I presented with 
rhythmic limb movements. At arrival to the emer-
gency room, blood glucose was 2.2 mmol/L. She 
suffered recurrent hypoglycaemic episodes, with 
critical samples taken on three occasions and 
showing low GH levels: 1.04 μg/L, 0.8 μg/L and 
2.45 μg/L with blood glucose concentrations of 
1.3 mmol/L, 0.8 mmol/L and 2.3 mmol/L, respec-
tively. She was started on somatotropin treat-
ment at 0.17 mg/kg/week and the hypoglycaemic 
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episodes decreased. She presented again at 11 months with a 
further episode of hypoglycaemia. Arginine stimulation testing 
confirmed GH deficiency with a peak GH level of 1.32 μg/L. 
Her somatotropin dose was adjusted to 0.18 mg/kg/week and 
her glycaemic control improved again. At age 2, a brain MRI 
revealed hypothalamic hypoplasia, with normal sella turcica. 
Her height increased from the 5th to the 25th percentile after 
treatment.
Her younger sister, patient 2-II, presented at 2 months with 
multiple hypoglycaemic episodes, including during an arginine 
stimulation test. GH was inappropriately low on multiple crit-
ical samples: 4.8 μg/L, 4.6 μg/L and 3.3 μg/L with blood glucose 
concentrations of 2.2 mmol/L, 2.8 mmol/L and 1.8 mmol/L, 
respectively. The rest of the endocrine and metabolic work-up 
was normal. She was treated with somatotropin at 0.23 mg/kg/
week, since her hypoglycaemia was more severe. Subsequently 
the dose was reduced to 0.185 mg/kg/week. After treatment 
her height increased from below the 3rd to the 25th percentile. 
Brain MRI at age 6 showed hypersignal of the pituitary stalk and 
posterior pituitary.
Patient 3-II developed seizures at 12 months, thought to have 
been precipitated by hypoglycaemia (glucose 2.4 mmol/L). At 
14 months of age her Insulin-like growth factor 1 (IGF-1) was 
27 μg/L (reference value 49–342 μg/L). Arginine stimulation 
testing revealed GH deficiency (GH peak value 4.1 μg/L). Her 
blood glucose was monitored leading to a decision not to start 
somatotropin treatment. At 3 years of age she presented again 
with hypoglycaemic seizures. A critical sample showed an 
insulin level of 26 pmol/L, GH was low at 0.08 μg/L, beta-hy-
droxybutyrate was 0.020 mmol/L (normal, 0.02–0.29 mmol/L) 
and free fatty acids was 263 µmol/L (normal, 100–900 µmol/L) 
for a glucose of 1.7 mmol/L. However, a second critical sample 
showed a fully suppressed insulin of <7 pmol/L and GH of 0.2 
μg/L, for a glucose of 2.5 mmol/L. Her blood glucose was moni-
tored regularly and the hypoglycaemic episodes have improved 
over time. She has not been treated with somatotropin.
Table 1 Clinical features of patients with Chitayat-Hall syndrome


















Age at last assessment 
(years)
35 13 11 10 8 6
Short stature + + + + + + 14/22
Increased 
subcutaneous fat
Noted in infancy, 
current BMI 19.4
NR NR + + + 9/20
Developmental delay/
intellectual disability
+ (moderate) + + + (severe) + (severe) + (severe) 22/22





− − + (myopia, hyperopia, 
exotropia)
16/20†
Dysmorphisms + + + + + + 25/30
Heart defect − + (patent foramen 
ovale)
− +(atrial septal defect) − − NR
Feeding problems + − − + + + 22/24
Gastro-oesophageal 
reflux
+ − − + + + 8/14
Contractures + + + + + + 25/30
Scoliosis/kyphosis + + + + + + 9/19
Hypoglycaemic 
episodes
− + + + + + 3/3‡
Growth hormone 
deficiency
+ + + + + + 1/1§
Hypothyroidism + − − − − − NR
Hypotonia + + + + + + 15/15








Frontal volume loss and 
decreased pituitary size
MRI not performed Thin pituitary stalk, 
dilatation of third 

















Karyotype, array genomic 
hybridisation
NR indicates that this information was not reported.
*Refs 4–6, 10–12.
†Esotropia, myopia and strabismus.
‡Hyperinsulinaemic hypoglycaemia10 and recurrent hypoglycaemia of unknown origin.11
§Ref 4.
BMI, body mass index. 
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Following the diagnosis of GH deficiency in her younger sister, 
patient 3-I was investigated. Her IGF-1 was low at <25 μg/L at 
3 years and 10 months and 28 μg/L at 6 years 1 month (reference 
value 49–342 μg/L). Arginine stimulation testing revealed a peak 
value of 2.7 μg/L. Her blood glucose was monitored, but the 
decision was made not to start somatotropin treatment. Brain 
MRI at 4 years showed a small pituitary gland.
Patient 4-I had hypoglycaemic episodes requiring hospitalisa-
tion at 6 months. GH deficiency was first suspected at 11 months 
and confirmed at 19 months. The GH measured during two 
hypoglycaemic episodes was low and a clonidine GH stimula-
tion test showed a deficiency (GH peak value 4.42 μg/L). The 
arginine GH stimulation test was also abnormal (4.435 mg intra-
venously ×1: GH peak value 3.53 μg/L). She was successfully 
treated with somatotropin. With treatment her height increased 
from below the 3rd to the 10th percentile. Brain MRI done at 
3 months and repeated at 3 years and 7 months revealed a thin 
pituitary stalk and slight dilation of the third ventricle, possibly 
secondary to hypothalamic atrophy.
Detailed results of GH stimulation testing can be found in 
online supplementary clinical information, tables 1–3.
MeThods
For all families, genetic analysis was performed by either whole 
genome sequencing (WGS) or whole exome sequencing (WES) 
with pathogenic variants confirmed by Sanger sequencing. For 
family 1, WGS of the proband and her father was performed. 
WES was performed on samples from affected patients in family 
2, and the probands in families 3 and 4 (online supplementary 
methods).
Analysis of WES and WGS data prioritised variants based on 
allele frequency, presence in databases of medically relevant vari-
ants including ClinVar7 and the Human Gene Mutation Data-
base,8 predicted impact on coding sequence, phenotype in the 
OMIM database, zygosity, and mode of inheritance. In family 2, 
where both affected individuals were sequenced, shared variants 
were examined. In family 1 variants shared between the proband 
and her unaffected father were prioritised due to the paternal 
family history of similarly affected individuals (figure 1, online 
supplementary figure 5).
Since MAGEL2 is expressed exclusively from the paternal 
allele, only pathogenic variants located on the paternal allele 
will cause disease.9 To determine the parental origin of the 
c.2179_2180del variant identified in family 3, long-range PCR 
of MAGEL2 followed by Sanger sequencing was performed on 
genomic DNA after methylation-sensitive digestion, as described 
previously4 (online supplementary methods).
sequenCIng resulTs
All affected individuals were found to carry truncating variants 
in MAGEL2. Patient 1-I was found to have a complex rear-
rangement interrupting the MAGEL2 gene, consisting of a 22 kb 
inversion and 3 kb deletion that removes the last 852 bp and 
the 3’ end of the gene (online supplementary figures 1–3). The 
variant was paternally inherited and segregation analysis for 
several additional family members was performed (figure 1). 
Siblings 2-I and 2-II have a nonsense variant (NM_019066; 
c.1762 C>T(p.Gln588Ter)) in MAGEL2. Parental samples were 
not available for testing. Patients 3-I and 3-II carry a frameshift 
variant (c.2179_2180del(p.Asp727Profs*6)) in MAGEL2. The 
Figure 1 pedigrees and MAGEL2 variants identified in patients with Chitayat-hall syndrome. Filled black squares and circles indicate clinically affected 
individuals, black dots indicate carriers, V indicates that the familial variant was found in an individual, + indicates the reference sequence and Nt indicates 
that the individual was not tested.
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variant was not present in parents or unaffected siblings, and was 
determined to be on the paternal allele (online supplementary 
figure 4). Patient 4-I has a previously reported frameshift inser-
tion (c.1996dupC(p.Gln666Profs*47))6 in MAGEL2, inherited 
from her unaffected father.
dIsCussIon
Multiple features first reported in Chitayat-Hall syndrome 
overlap with those described in the majority of individuals with 
SHFYNG, including contractures, hypotonia, developmental 
delay/intellectual disability, feeding difficulties, dysmorphisms, 
small hands and feet, and tapering fingers.1 4–6 10–12 Our cohort 
also has other features reported in a minority of individuals, 
including scoliosis, gastro-oesophageal reflux, increased subcu-
taneous fat and prominent ridge over the metopic suture. While 
eye abnormalities are described, this is the first report of micro-
cornea in patients with an MAGEL2-related disorder.6
The most common pathogenic sequence variant identified to 
date in MAGEL2, c.1996dupC(p.Gln666Profs*47), has been 
reported in 14 individuals from nine families diagnosed with 
SHFYNG.6 10 11 These individuals present with the features most 
commonly described in association with SHFYNG, including 
contractures, developmental delay/intellectual disability, dysmor-
phism, hypotonia and feeding difficulties. Short stature was 
reported in 6/14 cases. Our patient 4-I, with the c.1996dupC 
variant, has a very similar phenotype to the 14 reported patients, 
apart from her GH deficiency. Unfortunately, there is no infor-
mation available regarding GH levels in these 14 individuals.
Deficiency of hormones produced by the anterior pituitary 
is a prominent feature of Chitayat-Hall syndrome. All patients 
reported here demonstrated biochemical abnormalities related 
to GH deficiency on more than one occasion, with either low 
IGF-1, low GH peak after arginine stimulation, low GH in the 
context of hypoglycaemia, or all of the above. One patient with 
SHFYNG has been previously reported to have GH deficiency, 
presenting with poor linear growth and treated from 2 years of 
age.4 However, short stature is common in these patients, and is 
likely caused by undiagnosed GH deficiency in some cases.4 6 11 
Four patients in our study presented with hypoglycaemia, another 
manifestation of GH deficiency. Hypoglycaemic episodes have 
not been reported in the majority of patients with SHFYNG, 
although may go undiagnosed if not leading to convulsions or 
loss of consciousness.
The pathophysiology of GH deficiency in patients with 
MAGEL2 variants requires further investigation. MRI findings 
in our patients were not consistent, although it is notable that 
imaging for patients 2-I and 4-I demonstrated possible hypotha-
lamic hypoplasia. Magel2 is expressed in both fetal and adult 
brain,9 13 and mouse studies have demonstrated robust expres-
sion in the fetal hypothalamus. In adult mice Magel2 is mainly 
Figure 2 Features of affected patients. (A) patient I-1—myopathic faces with droopy eyelids and open mouth. (B,C) patients 2-I and 2-II, respectively—
both sisters had minor facial dysmorphism with a high forehead, a flat forehead in patient 2-I (B) and frontal bossing in patient 2-II (C) with a ridge over 
the metopic suture, deep set eyes, depressed nasal bridge with a broad nasal root and tip, and a ‘square’ chin with a horizontal groove over the chin. In 
patient 2-II (C) note the low-set ears with the right ear being lower than the left. (D) patient 3-I—high forehead with a ridge over the metopic suture, 
hypoplastic supraorbital ridges, deep set eyes, a broad nasal root and tip and a long philtrum, full cheeks, thin upper lip and retrognathia with a square 
chin and a horizontal groove over the chin. (e) hand of patient 3-II—‘puffy’ hand with proximally inserted thumb, tapering fingers and camptodactyly with 
absent distal flexion creases. (F) patient 3-II—deep set eyes, a broad nasal root and tip, long philtrum, thin upper lip, retrognathia, a ‘square’ chin with a 
horizontal groove over the chin and low-set ears. (G) patient 4-I—ridge over the metopic suture, deep set eyes, a broad nasal root and tip, thin upper lip, 
retrognathia with a square chin, a horizontal groove over the chin and low-set ears. (h) hand of patient 4-I—adducted thumb with the second and fifth 
fingers overlapping the third and fourth.
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expressed in the hypothalamus, including the arcuate nucleus 
where GH-releasing hormone (GHRH) is produced.14 15 There 
is evidence of GH deficiency related to hypothalamic dysfunc-
tion in the Magel2-null mouse. Tennese and Wevrick16 found 
low levels of IGF-1 in female Magel2-null mice compared with 
controls. The mice demonstrated a blunted response to hypo-
thalamic stimulation of the GH pathway with ghrelin compared 
with wild-type littermates, while their response to GHRH was 
equivalent, indicating a possible hypothalamic origin for the 
deficiency.16
Family 1 carries a complex rearrangement and partial 
deletion. To our knowledge this is the first report of such a 
change causing an MAGEL2-related disorder. The first 2.9 kb 
of the coding and the 5’ region are apparently intact, and it 
is possible that a truncated protein product is produced. It 
has been suggested that frameshift and nonsense variants in 
MAGEL2 escape nonsense-mediated decay and have a neomor-
phic or dominant negative effect, explaining the milder pheno-
type seen in full gene deletions.6 17 18 Functional studies are 
required to investigate this possibility, but are difficult to 
pursue given that the expression of MAGEL2 in adult tissues 
is very limited.9 13 This case illustrates the benefits of WGS 
as a diagnostic test, as this complex variant would not have 
been detected using exome, microarray or targeted sequencing 
methodologies.
In family 3 we demonstrated that the variant identified in 
the two affected sisters was on the paternal allele. It was not 
detectable in paternal blood by Sanger sequencing. This does 
not rule out the possibility of low level mosaicism in blood or 
other tissues. This is the third reported case of apparent mosa-
icism in an unaffected father in MAGEL2-related disorder.10 11 
In this situation, the recurrence risk could be up to 50%.
The phenotype of MAGEL2-related disorder continues to 
evolve, now including Chitayat-Hall syndrome. With the excep-
tion of the endocrinological findings we describe, our patients’ 
phenotypes are very similar to those observed in patients with 
SHFYNG, and one of our patients carries the most common 
recurrent variant c.1996dupC reported in SHFYNG. This 
suggests that SHFYNG and Chitayat-Hall syndromes are likely 
the same disorder. A systematic investigation of endocrinolog-
ical abnormalities in patients with MAGEL2-related disorder is 
needed and GH deficiency should always be considered in the 
context of poor growth and/or hypoglycaemia.
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